The planned implementation of Medicaid work requirements provides an opportunity to obtain longitudinal data to guide ...

Tobacco use kills more than 7 million people worldwide each year, including 1.3 million who die from the effects of exposure to secondhand smoke.1 As a major contributor to cancer, cardiovascular ...

Patients benefit from antiplatelet therapy after coronary-artery bypass grafting (CABG) for an acute coronary syndrome.

There is an urgent need for low- and middle-income countries to ensure equitable, affordable, and sustained access to tobacco-cessation medications at scale.

We randomly assigned, in a 2:2:1 ratio, participants with previously untreated EGFR -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive ...

Enactment of the Mental Health Parity and Addiction Equity Act in 2008 improved insurance coverage for mental health and addiction treatment. Now, the Affordable Care Act could affect the financing ...

HCM is the most common inherited heart disease worldwide and is associated with considerable disease-related morbidity. A substantial subpopulation of patients with HCM have disease characterized by a ...

Venous thromboembolism is a common complication of cancer and its treatments, and the incidence of recurrent thrombosis, serious bleeding, and death is higher among patients with this condition than ...

Starting in January 2025, various government health datasets were removed, restored, manipulated, or not posted as planned. The consequences of these changes could be far-reaching.

In this international, randomized trial, we assigned critically ill adults who were undergoing invasive ventilation to receive intravenous pantoprazole (at a dose of 40 mg daily) or matching placebo.

Systems for reporting adverse events can reduce medical errors by uncovering remediable problems in processes of care; however, current reporting systems are neither widely used nor highly effective.

To the Editor: In the SELECT trial, Lincoff and colleagues (Dec. 14 issue) 1 found that weekly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was superior to placebo in ...